Sells it 13%, $6.5B a quarter“CarelonRx growth reflected higher average revenue per prescription, with specialty pharmacy profitability supporting its gain.”
Latest 10-QQ3 FY2026Mixed ·
Carelon’s specialty pharmacy and care-services gains fell short of offsetting medical-cost pressure in Health Benefits.
Revenue$51.4BYoY +1.4%
Net income$1.4BYoY +14.8%
Latest 8-KGuidance reaffirmed ·
FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.
Latest 8-KPositiveEarningsGuidance raised ·
Carelon growth contrasts with Health Benefits weakness; FY2026 adjusted EPS outlook raised to ≥$29
Sells it 82%, $91.4B a quarter“Revenue grew 8% in both Q2 and H1, reflecting North American Pharmaceutical market growth—including higher institutional and retail national-account volumes, drug utilization such as GLP-1 medicines, and new launches—and increased specialty-drug sales in Oncology & Multispecialty.”
Latest 10-QQ2 FY2027Restructuring ·
Precision Medicine Group and Spectrum Vision acquisitions expand specialty care as separation costs squeeze Medical-Surgical profit.
Revenue$111.0BYoY +7.6%
Net income$1.2BYoY +9.7%
Latest 8-KPositiveEarningsGuidance raised ·
Prescription volumes and specialty distribution drive growth as FY2027 adjusted EPS outlook rises; CVS Health partnership extended through June 2032.